These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 7493196)

  • 1. Design and assessment of cost-effectiveness studies in AIDS populations.
    Simpson KN
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S28-32. PubMed ID: 7493196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific considerations for cost-effectiveness studies in AIDS.
    Bozzette SA
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S23-7. PubMed ID: 7493195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
    Bennett CL; Oddone E; Matchar D
    Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding the essentials of economic evaluation.
    Schmid GP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S6-13. PubMed ID: 7493197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Working toward a common currency: is standardization of cost-effectiveness analysis possible?
    Luce BR
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S19-22. PubMed ID: 7493194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevention of wasting and opportunistic infections in HIV-infected patients in West Africa: a realistic and necessary strategy before antiretroviral treatment].
    Ledru é ; Sanou PT; Dembele M; Dahourou H; Zoubga A; Durand G
    Sante; 1999; 9(5):293-300. PubMed ID: 10657773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive chemotherapy for HIV-associated tuberculosis in Uganda: an operational assessment at a voluntary counselling and testing centre.
    Aisu T; Raviglione MC; van Praag E; Eriki P; Narain JP; Barugahare L; Tembo G; McFarland D; Engwau FA
    AIDS; 1995 Mar; 9(3):267-73. PubMed ID: 7755915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Who should be screened for HIV infection? A cost-effectiveness analysis.
    McCarthy BD; Wong JB; Muñoz A; Sonnenberg FA
    Arch Intern Med; 1993 May; 153(9):1107-16. PubMed ID: 8481077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness: from whose perspective?
    Hillman AL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S14-8. PubMed ID: 7493193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the cost-effectiveness of pharmacologic therapy: where we've been and where we're going.
    Epstein AM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S1-5. PubMed ID: 7493192
    [No Abstract]   [Full Text] [Related]  

  • 15. [How to balance the antiretrovirus drugs and cost in China].
    Li TS
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(17):1153-4. PubMed ID: 22882999
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost effectiveness and AIDS: science or marketing? Proceedings of a workshop. Washington, D.C., January 28, 1995.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 4():S1-32. PubMed ID: 7493191
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of drug use and cost of hospital care for AIDS patients between 1990 and 1994.
    Peyron F; Flori A; Galliano-di Bernardo Bernardo S; Moreau J; Buès-Charbit M; Balansard G
    Pharm World Sci; 1997 Aug; 19(4):202-7. PubMed ID: 9297734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV/AIDS issues take centre-stage at World Health Assembly.
    Kapp C
    Lancet; 2000 May; 355(9218):1894. PubMed ID: 10866457
    [No Abstract]   [Full Text] [Related]  

  • 19. International expenditure projections for pharmacotherapeutic advances in the treatment of HIV/AIDS.
    Sclar DA; Robison LM; Skaer TL; Terriff CM; Garrison MW
    Clin Ther; 1997; 19(1):86-95; discussion 84-5. PubMed ID: 9083711
    [No Abstract]   [Full Text] [Related]  

  • 20. Treating AIDS: the economic issues.
    Drummond M; Davies L
    Health Policy; 1988 Aug; 10(1):1-19. PubMed ID: 10312592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.